ClinicalTrials.gov
public full text
Public Domain
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)#1350948
- Etoposide in Patients With COVID-19 Infection#1350822
- A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects#912110
- Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department#1260809
- Quality of Life After Hyperbaric Oxygen Therapy in Post-COVID Patients#1088320
Record · ID 1293317
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive